Oral paricalcitol as antiproteinuric agent in chronic kidney disease

Statistics

Paricalcitol oral como agente antiproteinúrico en la enfermedad renal crónica

Alberto de Lorenzoa, Alberto de Lorenzob, Laura Salanovaa, Laura Salanovab, Andrew S. Bombackc, Andrew S. Bombackd, María Moyaa, Maria Moyab, Francisco Coronele, Carmen Bernisa, Carmen Bernisb, José A. Sánchez-Tomeroa, José Antonio Sánchez-Tomerob, Vicente Álvareza, Vicente Álvarezb

a Servicio de Nefrología, Hospital Universitario de La Princesa, Madrid, Spain,

b Servicio de Nefrología, Hospital Universitario de La Princesa, Madrid, Madrid, España,

c Division of Nephrology, Columbia University College of Physicians and Surgeons, Presbyterian Hospital, New York, USA,

d Division of Nephrology, Columbia University College of Physicians and Surgeons, Presbyterian Hospital, New York, New York, USA,

e Servicio de Nefrología, Hospital Clinico Universitario San Carlos, Madrid, Madrid, España,

Read

9795

Times
was read the article

2629

Total PDF

7166

Total HTML

Share statistics

Article information

ISSN: 20132514
Original language: English

DOI:10.3265/Nefrologia.pre2013.Jun.11928

The statistics are updated each day

Year/Month	Html	Pdf	Total

2025 6	14	29	43
2025 5	71	35	106
2025 4	66	25	91
2025 3	78	47	125
2025 2	81	30	111
2025 1	64	50	114
2024 12	65	26	91
2024 11	72	47	119
2024 10	56	36	92
2024 9	52	23	75
2024 8	73	58	131
2024 7	47	30	77
2024 6	63	31	94
2024 5	81	29	110
2024 4	69	39	108
2024 3	53	21	74
2024 2	49	30	79
2024 1	52	20	72
2023 12	50	24	74
2023 11	59	31	90
2023 10	56	37	93
2023 9	53	25	78
2023 8	53	21	74
2023 7	47	25	72
2023 6	54	20	74
2023 5	55	29	84
2023 4	48	19	67
2023 3	74	21	95
2023 2	44	16	60
2023 1	47	27	74
2022 12	79	35	114
2022 11	75	28	103
2022 10	66	37	103
2022 9	44	35	79
2022 8	85	46	131
2022 7	57	47	104
2022 6	38	30	68
2022 5	37	32	69
2022 4	35	46	81
2022 3	36	39	75
2022 2	47	50	97
2022 1	63	26	89
2021 12	42	44	86
2021 11	35	40	75
2021 10	45	43	88
2021 9	30	28	58
2021 8	31	39	70
2021 7	36	29	65
2021 6	26	23	49
2021 5	29	41	70
2021 4	53	44	97
2021 3	59	35	94
2021 2	41	24	65
2021 1	53	13	66
2020 12	47	18	65
2020 11	41	12	53
2020 10	34	23	57
2020 9	27	7	34
2020 8	37	8	45
2020 7	30	10	40
2020 6	30	21	51
2020 5	31	17	48
2020 4	31	18	49
2020 3	33	13	46
2020 2	37	27	64
2020 1	44	37	81
2019 12	48	25	73
2019 11	46	29	75
2019 10	9	9	18
2019 9	26	23	49
2019 8	25	19	44
2019 7	26	21	47
2019 6	27	13	40
2019 5	20	17	37
2019 4	64	40	104
2019 3	40	18	58
2019 2	27	14	41
2019 1	32	29	61
2018 12	99	35	134
2018 11	106	18	124
2018 10	69	18	87
2018 9	67	15	82
2018 8	53	21	74
2018 7	44	14	58
2018 6	40	14	54
2018 5	47	11	58
2018 4	35	8	43
2018 3	46	10	56
2018 2	43	16	59
2018 1	48	6	54
2017 12	50	9	59
2017 11	39	13	52
2017 10	42	9	51
2017 9	58	9	67
2017 8	37	14	51
2017 7	28	15	43
2017 6	31	5	36
2017 5	39	9	48
2017 4	42	19	61
2017 3	28	7	35
2017 2	41	22	63
2017 1	24	12	36
2016 12	76	21	97
2016 11	90	15	105
2016 10	130	13	143
2016 9	133	7	140
2016 8	240	9	249
2016 7	201	12	213
2016 6	157	0	157
2016 5	148	0	148
2016 4	115	0	115
2016 3	99	0	99
2016 2	124	0	124
2016 1	145	0	145
2015 12	124	0	124
2015 11	103	0	103
2015 10	98	0	98
2015 9	77	0	77
2015 8	70	0	70
2015 7	59	0	59
2015 6	52	0	52
2015 5	55	0	55
2015 4	14	0	14

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter